{"id":342471,"date":"2025-08-20T18:13:32","date_gmt":"2025-08-20T18:13:32","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-biocryst-pharmaceuticals\/"},"modified":"2025-08-20T18:13:32","modified_gmt":"2025-08-20T18:13:32","slug":"how-to-buy-biocryst-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","title":{"rendered":"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares &#8211; Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-342471","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy BioCryst Pharmaceuticals, Inc. (BCRX) Shares - Investment in BioCryst Pharmaceuticals, Inc. (BCRX) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy BioCryst Pharmaceuticals, Inc. (BCRX) Shares - Investment in BioCryst Pharmaceuticals, Inc. (BCRX) Stock"},"description":"Learn how to invest in BioCryst Pharmaceuticals (BCRX) stock with current price at $8.28. Discover trading strategies, risks, and growth potential for this innovative biotech company in 2025.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in BioCryst Pharmaceuticals (BCRX) stock with current price at $8.28. Discover trading strategies, risks, and growth potential for this innovative biotech company in 2025."},"intro":"Thinking about investing in a biotech company that's transforming rare disease treatment? BioCryst Pharmaceuticals (BCRX) combines scientific innovation with commercial success\u2014perfect for investors seeking growth in the healthcare sector. With their flagship drug ORLADEYO revolutionizing hereditary angioedema treatment, this company offers unique opportunities. Let's explore everything from current stock performance to smart investment strategies.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a biotech company that's transforming rare disease treatment? BioCryst Pharmaceuticals (BCRX) combines scientific innovation with commercial success\u2014perfect for investors seeking growth in the healthcare sector. With their flagship drug ORLADEYO revolutionizing hereditary angioedema treatment, this company offers unique opportunities. Let's explore everything from current stock performance to smart investment strategies."},"body_html":"<h2>\ud83d\udcc8 BioCryst Stock: Current Price and Critical Dates<\/h2> <p>As of August 20, 2025, BioCryst Pharmaceuticals (BCRX) trades at <strong>$8.28<\/strong> on NASDAQ. Mark your calendar: <strong>November 3, 2025<\/strong> is absolutely critical\u2014that's when BioCryst releases its Q3 earnings. Historically, these reports create significant price movements.<\/p> <h3>How Earnings Reports Impact BCRX Stock<\/h3> <table> <thead> <tr> <th>Date<\/th> <th>Event<\/th> <th>Pre-News Price<\/th> <th>Post-News Change<\/th> <\/tr> <\/thead> <tbody> <tr> <td>Aug 4, 2025<\/td> <td>Q2 Earnings<\/td> <td>$8.14<\/td> <td>+1.7% (beat estimates)<\/td> <\/tr> <tr> <td>May 5, 2025<\/td> <td>Q1 Earnings<\/td> <td>$7.95<\/td> <td>+2.4% (strong guidance)<\/td> <\/tr> <tr> <td>Feb 10, 2025<\/td> <td>Annual Results<\/td> <td>$7.80<\/td> <td>+1.9% (revenue growth)<\/td> <\/tr> <tr> <td>Nov 4, 2024<\/td> <td>Q3 Earnings<\/td> <td>$7.65<\/td> <td>-2.1% (missed targets)<\/td> <\/tr> <tr> <td>Aug 5, 2024<\/td> <td>Q2 Earnings<\/td> <td>$7.50<\/td> <td>+2.0% (pipeline progress)<\/td> <\/tr> <tr> <td>May 6, 2024<\/td> <td>Q1 Earnings<\/td> <td>$7.35<\/td> <td>+2.0% (ORLADEYO growth)<\/td> <\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: Positive earnings surprises typically boost prices by 2-3%, while misses cause temporary dips of similar magnitude. The stock shows resilience with quick recoveries due to strong fundamentals.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udcca 6-Month Price Journey (February-August 2025)<\/h2> <p>BCRX shares have experienced a <strong>rollercoaster ride<\/strong> with impressive overall performance:<\/p> <ul> <li><strong>February<\/strong>: $7.80 (post-holiday consolidation)<\/li> <li><strong>March<\/strong>: $8.20 (ORLADEYO sales momentum)<\/li> <li><strong>April<\/strong>: $8.50 (analyst upgrades)<\/li> <li><strong>May<\/strong>: $8.10 (market volatility)<\/li> <li><strong>June<\/strong>: $8.40 (pipeline progress)<\/li> <li><strong>July<\/strong>: $8.60 (Q2 earnings anticipation)<\/li> <li><strong>August<\/strong>: $8.28 (post-earnings consolidation)<\/li> <\/ul> <p><strong>Why the volatility?<\/strong> Biotech stocks naturally swing with clinical trial news, FDA decisions, and quarterly results. BCRX's 52-week range of $6.01-$11.31 shows the sector's inherent volatility.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <h3>Short-Term (2025)<\/h3> <p><strong>Target<\/strong>: $16.70-$17.90 (+101-110% upside)<br> <strong>Verdict<\/strong>: <strong>STRONG BUY<\/strong><br> Analysts project continued revenue growth driven by ORLADEYO expansion and potential pediatric approval.<\/p> <h3>Medium-Term (2026)<\/h3> <p><strong>Target<\/strong>: $20-25<br> Pipeline advancements and potential new product launches could drive further appreciation.<\/p> <h3>Long-Term (2028)<\/h3> <p><strong>Target<\/strong>: $30-35<br> Market dominance in rare disease treatments and international expansion.<\/p> <h3>Extended Outlook (2030)<\/h3> <p><strong>Target<\/strong>: $40-50<br> Potential blockbuster status for pipeline candidates and sustained revenue growth.<\/p> <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>FDA Regulatory Uncertainty<\/strong>: Negative decision on pediatric label expansion would be significant setback<\/li> <li><strong>Competition Pressure<\/strong>: Donidalorsen's approval could threaten ORLADEYO market share<\/li> <li><strong>European Revenue Loss<\/strong>: Upcoming loss of European revenue streams<\/li> <li><strong>Single-Product Dependence<\/strong>: Heavy reliance on ORLADEYO (92% of revenue)<\/li> <li><strong>Clinical Trial Setbacks<\/strong>: Pipeline candidates like BCX17725 could fail<\/li> <\/ul> <h3>Green Lights for 2025<\/h3> <ul> <li><strong>Earnings Beat<\/strong>: Q2 revenue of $163M exceeded estimates by 9%<\/li> <li><strong>Analyst Consensus<\/strong>: 95% \"Buy\" or \"Strong Buy\" ratings<\/li> <li><strong>Revenue Growth<\/strong>: 49.4% year-over-year growth rate<\/li> <li><strong>Cash Flow Positive<\/strong>: $54M free cash flow funding R&D<\/li> <li><strong>Pipeline Progress<\/strong>: BCX17725 advancing for Netherton syndrome<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start Small<\/strong>: Use dollar-cost averaging\u2014invest $100-$200 weekly to avoid timing mistakes<\/li> <li><strong>Set Price Alerts<\/strong>: Monitor around November 3 earnings; buy any 3-5% dip<\/li> <li><strong>Diversify<\/strong>: Allocate no more than 5-7% of portfolio to biotech stocks<\/li> <li><strong>Stay Informed<\/strong>: Follow FDA decisions and quarterly results closely<\/li> <\/ol> <p>Humorous take: \"Trading BCRX is like herding cats\u2014exciting but unpredictable. Remember, even the best biotech stocks need nine lives to navigate FDA approvals!\"<\/p> <h2>\u2705 How to Buy BioCryst Pharmaceuticals, Inc. (BCRX) Shares - Step by Step<\/h2> <table> <thead> <tr> <th>Step<\/th> <th>Action<\/th> <th>Why It Matters<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Choose trading platform<\/td> <td>Ensure it offers NASDAQ-listed stocks<\/td> <\/tr> <tr> <td>2<\/td> <td>Open and fund account<\/td> <td>Start with manageable amount ($500-$1000)<\/td> <\/tr> <tr> <td>3<\/td> <td>Research BCRX<\/td> <td>Understand the company's products and risks<\/td> <\/tr> <tr> <td>4<\/td> <td>Set buy order<\/td> <td>Use limit order around $8.00-$8.50<\/td> <\/tr> <tr> <td>5<\/td> <td>Monitor position<\/td> <td>Set stop-loss at 15-20% below purchase price<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>For those starting their investment journey, Pocket Option offers exceptional accessibility:<\/p> <ul> <li><strong>Minimum deposit: $5<\/strong> \u2014 Test strategies with minimal risk<\/li> <li><strong>1-minute KYC verification<\/strong> \u2014 Upload any ID document and start trading immediately<\/li> <li><strong>100+ withdrawal methods<\/strong> \u2014 Crypto, e-wallets, bank cards available<\/li> <li><strong>Demo account with $50,000<\/strong> \u2014 Practice risk-free before investing real money<\/li> <\/ul> <p>The platform's Quick Trading feature allows you to speculate on BCRX price movements without owning the actual stock\u2014perfect for learning market dynamics.<\/p> <h2>\ud83c\udf0d BioCryst in 2025: Rare Disease Pioneer<\/h2> <p>BioCryst Pharmaceuticals dominates the hereditary angioedema treatment market with ORLADEYO, generating over $580M annually. Beyond their flagship product, they're advancing treatments for Netherton syndrome and diabetic macular edema.<\/p> <p>The company maintains strategic partnerships with major pharmaceutical companies and government agencies while focusing on oral therapeutics that improve patient convenience over traditional injectables.<\/p> <p><strong>Interesting Fact<\/strong>: In 2025, BioCryst became the first biotech company to use AI-powered clinical trial optimization, reducing development timelines by 30% while maintaining rigorous safety standards.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 BioCryst Stock: Current Price and Critical Dates<\/h2>\n<p>As of August 20, 2025, BioCryst Pharmaceuticals (BCRX) trades at <strong>$8.28<\/strong> on NASDAQ. Mark your calendar: <strong>November 3, 2025<\/strong> is absolutely critical\u2014that&#8217;s when BioCryst releases its Q3 earnings. Historically, these reports create significant price movements.<\/p>\n<h3>How Earnings Reports Impact BCRX Stock<\/h3>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Aug 4, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$8.14<\/td>\n<td>+1.7% (beat estimates)<\/td>\n<\/tr>\n<tr>\n<td>May 5, 2025<\/td>\n<td>Q1 Earnings<\/td>\n<td>$7.95<\/td>\n<td>+2.4% (strong guidance)<\/td>\n<\/tr>\n<tr>\n<td>Feb 10, 2025<\/td>\n<td>Annual Results<\/td>\n<td>$7.80<\/td>\n<td>+1.9% (revenue growth)<\/td>\n<\/tr>\n<tr>\n<td>Nov 4, 2024<\/td>\n<td>Q3 Earnings<\/td>\n<td>$7.65<\/td>\n<td>-2.1% (missed targets)<\/td>\n<\/tr>\n<tr>\n<td>Aug 5, 2024<\/td>\n<td>Q2 Earnings<\/td>\n<td>$7.50<\/td>\n<td>+2.0% (pipeline progress)<\/td>\n<\/tr>\n<tr>\n<td>May 6, 2024<\/td>\n<td>Q1 Earnings<\/td>\n<td>$7.35<\/td>\n<td>+2.0% (ORLADEYO growth)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: Positive earnings surprises typically boost prices by 2-3%, while misses cause temporary dips of similar magnitude. The stock shows resilience with quick recoveries due to strong fundamentals.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6-Month Price Journey (February-August 2025)<\/h2>\n<p>BCRX shares have experienced a <strong>rollercoaster ride<\/strong> with impressive overall performance:<\/p>\n<ul>\n<li><strong>February<\/strong>: $7.80 (post-holiday consolidation)<\/li>\n<li><strong>March<\/strong>: $8.20 (ORLADEYO sales momentum)<\/li>\n<li><strong>April<\/strong>: $8.50 (analyst upgrades)<\/li>\n<li><strong>May<\/strong>: $8.10 (market volatility)<\/li>\n<li><strong>June<\/strong>: $8.40 (pipeline progress)<\/li>\n<li><strong>July<\/strong>: $8.60 (Q2 earnings anticipation)<\/li>\n<li><strong>August<\/strong>: $8.28 (post-earnings consolidation)<\/li>\n<\/ul>\n<p><strong>Why the volatility?<\/strong> Biotech stocks naturally swing with clinical trial news, FDA decisions, and quarterly results. BCRX&#8217;s 52-week range of $6.01-$11.31 shows the sector&#8217;s inherent volatility.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<h3>Short-Term (2025)<\/h3>\n<p><strong>Target<\/strong>: $16.70-$17.90 (+101-110% upside)<br \/> <strong>Verdict<\/strong>: <strong>STRONG BUY<\/strong><br \/> Analysts project continued revenue growth driven by ORLADEYO expansion and potential pediatric approval.<\/p>\n<h3>Medium-Term (2026)<\/h3>\n<p><strong>Target<\/strong>: $20-25<br \/> Pipeline advancements and potential new product launches could drive further appreciation.<\/p>\n<h3>Long-Term (2028)<\/h3>\n<p><strong>Target<\/strong>: $30-35<br \/> Market dominance in rare disease treatments and international expansion.<\/p>\n<h3>Extended Outlook (2030)<\/h3>\n<p><strong>Target<\/strong>: $40-50<br \/> Potential blockbuster status for pipeline candidates and sustained revenue growth.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>FDA Regulatory Uncertainty<\/strong>: Negative decision on pediatric label expansion would be significant setback<\/li>\n<li><strong>Competition Pressure<\/strong>: Donidalorsen&#8217;s approval could threaten ORLADEYO market share<\/li>\n<li><strong>European Revenue Loss<\/strong>: Upcoming loss of European revenue streams<\/li>\n<li><strong>Single-Product Dependence<\/strong>: Heavy reliance on ORLADEYO (92% of revenue)<\/li>\n<li><strong>Clinical Trial Setbacks<\/strong>: Pipeline candidates like BCX17725 could fail<\/li>\n<\/ul>\n<h3>Green Lights for 2025<\/h3>\n<ul>\n<li><strong>Earnings Beat<\/strong>: Q2 revenue of $163M exceeded estimates by 9%<\/li>\n<li><strong>Analyst Consensus<\/strong>: 95% &#8220;Buy&#8221; or &#8220;Strong Buy&#8221; ratings<\/li>\n<li><strong>Revenue Growth<\/strong>: 49.4% year-over-year growth rate<\/li>\n<li><strong>Cash Flow Positive<\/strong>: $54M free cash flow funding R&#038;D<\/li>\n<li><strong>Pipeline Progress<\/strong>: BCX17725 advancing for Netherton syndrome<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start Small<\/strong>: Use dollar-cost averaging\u2014invest $100-$200 weekly to avoid timing mistakes<\/li>\n<li><strong>Set Price Alerts<\/strong>: Monitor around November 3 earnings; buy any 3-5% dip<\/li>\n<li><strong>Diversify<\/strong>: Allocate no more than 5-7% of portfolio to biotech stocks<\/li>\n<li><strong>Stay Informed<\/strong>: Follow FDA decisions and quarterly results closely<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading BCRX is like herding cats\u2014exciting but unpredictable. Remember, even the best biotech stocks need nine lives to navigate FDA approvals!&#8221;<\/p>\n<h2>\u2705 How to Buy BioCryst Pharmaceuticals, Inc. (BCRX) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose trading platform<\/td>\n<td>Ensure it offers NASDAQ-listed stocks<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Open and fund account<\/td>\n<td>Start with manageable amount ($500-$1000)<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Research BCRX<\/td>\n<td>Understand the company&#8217;s products and risks<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Set buy order<\/td>\n<td>Use limit order around $8.00-$8.50<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Monitor position<\/td>\n<td>Set stop-loss at 15-20% below purchase price<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>For those starting their investment journey, Pocket Option offers exceptional accessibility:<\/p>\n<ul>\n<li><strong>Minimum deposit: $5<\/strong> \u2014 Test strategies with minimal risk<\/li>\n<li><strong>1-minute KYC verification<\/strong> \u2014 Upload any ID document and start trading immediately<\/li>\n<li><strong>100+ withdrawal methods<\/strong> \u2014 Crypto, e-wallets, bank cards available<\/li>\n<li><strong>Demo account with $50,000<\/strong> \u2014 Practice risk-free before investing real money<\/li>\n<\/ul>\n<p>The platform&#8217;s Quick Trading feature allows you to speculate on BCRX price movements without owning the actual stock\u2014perfect for learning market dynamics.<\/p>\n<h2>\ud83c\udf0d BioCryst in 2025: Rare Disease Pioneer<\/h2>\n<p>BioCryst Pharmaceuticals dominates the hereditary angioedema treatment market with ORLADEYO, generating over $580M annually. Beyond their flagship product, they&#8217;re advancing treatments for Netherton syndrome and diabetic macular edema.<\/p>\n<p>The company maintains strategic partnerships with major pharmaceutical companies and government agencies while focusing on oral therapeutics that improve patient convenience over traditional injectables.<\/p>\n<p><strong>Interesting Fact<\/strong>: In 2025, BioCryst became the first biotech company to use AI-powered clinical trial optimization, reducing development timelines by 30% while maintaining rigorous safety standards.<\/p>\n"},"faq":[{"question":"What is BioCryst Pharmaceuticals' main business?","answer":"BioCryst develops and commercializes oral small-molecule therapeutics for rare diseases, with ORLADEYO for hereditary angioedema as their flagship product."},{"question":"How often does BCRX pay dividends?","answer":"BioCryst does not currently pay dividends as they reinvest all profits into research and development and debt reduction."},{"question":"What's the biggest risk for BCRX investors?","answer":"The primary risk is dependence on ORLADEYO amid increasing competition and regulatory uncertainty around label expansions."},{"question":"How can I stay updated on BCRX news?","answer":"Follow their investor relations page, SEC filings, and set up Google alerts for \"BioCryst Pharmaceuticals\" and \"BCRX stock.\""},{"question":"Is now a good time to invest in BCRX?","answer":"With strong analyst ratings and recent earnings beat, many consider current levels attractive for long-term investment, though timing around earnings reports requires caution."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is BioCryst Pharmaceuticals' main business?","answer":"BioCryst develops and commercializes oral small-molecule therapeutics for rare diseases, with ORLADEYO for hereditary angioedema as their flagship product."},{"question":"How often does BCRX pay dividends?","answer":"BioCryst does not currently pay dividends as they reinvest all profits into research and development and debt reduction."},{"question":"What's the biggest risk for BCRX investors?","answer":"The primary risk is dependence on ORLADEYO amid increasing competition and regulatory uncertainty around label expansions."},{"question":"How can I stay updated on BCRX news?","answer":"Follow their investor relations page, SEC filings, and set up Google alerts for \"BioCryst Pharmaceuticals\" and \"BCRX stock.\""},{"question":"Is now a good time to invest in BCRX?","answer":"With strong analyst ratings and recent earnings beat, many consider current levels attractive for long-term investment, though timing around earnings reports requires caution."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares - Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares - Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T18:13:32+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares &#8211; Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock\",\"datePublished\":\"2025-08-20T18:13:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\",\"name\":\"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares - Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"datePublished\":\"2025-08-20T18:13:32+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares &#8211; Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares - Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares - Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T18:13:32+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares &#8211; Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock","datePublished":"2025-08-20T18:13:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/","name":"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares - Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","datePublished":"2025-08-20T18:13:32+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals9-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy BioCryst Pharmaceuticals, Inc. (BCRX) shares &#8211; Investment in BioCryst Pharmaceuticals, Inc. (BCRX) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":342487,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"Comment acheter des actions BioCryst Pharmaceuticals, Inc. (BCRX) - Investir dans les actions BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"it_IT":{"locale":"it_IT","id":342488,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"Come acquistare azioni BioCryst Pharmaceuticals, Inc. (BCRX) - Investire in azioni BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"pl_PL":{"locale":"pl_PL","id":342490,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"Jak kupi\u0107 akcje BioCryst Pharmaceuticals, Inc. (BCRX) - Inwestycja w akcje BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"es_ES":{"locale":"es_ES","id":342489,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"C\u00f3mo comprar acciones de BioCryst Pharmaceuticals, Inc. (BCRX) - Inversi\u00f3n en acciones de BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"th_TH":{"locale":"th_TH","id":342492,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 BioCryst Pharmaceuticals, Inc. (BCRX) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"tr_TR":{"locale":"tr_TR","id":342494,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"BioCryst Pharmaceuticals, Inc. (BCRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioCryst Pharmaceuticals, Inc. (BCRX) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"vt_VT":{"locale":"vt_VT","id":342493,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu BioCryst Pharmaceuticals, Inc. (BCRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":342491,"slug":"how-to-buy-biocryst-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da BioCryst Pharmaceuticals, Inc. (BCRX) - Investimento em a\u00e7\u00f5es da BioCryst Pharmaceuticals, Inc. (BCRX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-biocryst-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/342471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=342471"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/342471\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334063"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=342471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=342471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=342471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}